Stem Cells: An Alternative Therapy for COVID-19 and Cytokine Storm provides mechanistic insights into the role of stem cells to combat COVID-19 outbreak and other pathologies where cytokines storm is the cause of concern for e.g., radiation exposure, multiple organ failure and sepsis. There has been an increase in number of cases of new diseases in the last decade, including mucormycosis, Zika virus, H1N1 influenza virus, among others. These diseases can be characterized by the induction of cytokine storm, which is mainly responsible for morbidity and mortality.
Stem cell therapy has emerged as a potential treatment for viral diseases, including, but not limited to, COVID-19. Interestingly, clinical trials in patients with COVID-19 complications depicted faster recovery in patients post mesenchymal stem cells therapy owing to the decreased cytokines levels, anti-viral effects and regeneration of the infected tissue.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
- Targets of SARS-CoV-2: Therapeutic Implications for COVID-19
- COVID-19 Biology: Cytokine Storms and Their Implications
- Comparative Clinical Investigation of Blood Profiling in COVID-19 Patients
- SARS-CoV-2 Associated Complications
- COVID-19 Diagnostic Approaches and Modern Mesenchymal Stem Cell-based Treatment
- Modulation of Pentose Phosphate Pathway Augments the Efficacy of 2-deoxy-D-glucose in COVID-19 Management
- Therapeutic Landscape of SARS-CoV-2
- Pharmacotherapeutics for Cytokine Storm in COVID-19
- Clinical Investigation of COVID-19 Prevention and Treatment
- Potential Therapeutic Landscape of COVID-19: Molecular Targets, Repurposed Drugs, and Nano- and Cell-based Intervention
- Medical Care for SARS-CoV-2
- Therapeutic Approaches for Opportunistic Infection Post-COVID-19
- Focusing on the Cytokine Storm in the Battle Against COVID-19: The Rising Role of Mesenchymal-derived Stem Cells
- Cytokine Storm in COVID-19 and Other Diseases: Emerging Therapeutic Interventions
- Stem Cells as Therapeutics and Their Implications in Cytokine Storm in COVID-19
- Visualizing Chemical Functionality and Structural Insights into SARS-CoV-2 Proteins
- Mesenchymal Stromal Cells and Pleiotropic Therapeutic Advantages in COVID-19 Management
- Mesenchymal Stem Cells Role in Tuberculosis Pathogenesis and Persistence
- Radiosensitivity of Cancer Stem Cells Holds Promise for the Outcome in Radiotherapy and COVID-19 Infections
- Immunomodulatory Therapeutic Potential of Mesenchymal Stem Cells in COVID-19 Pathogenesis
- Clinical Limitations of Stem Cell Therapy
- Clinical Limitations in Stem Cell Therapy
- Stem Cell Based Products and the Regulatory Hurdle Race
- Implications of Stem Cell Therapy on the Socio-Scientific Community
Authors
Yogesh Kumar Verma Scientist 'E', Stem Cell and Gene Therapy Research Group, Institute of Nuclear Medicine and Allied Sciences, Delhi, India. Dr. Yogesh Kumar Verma, MNABS, is working as Scientist 'E' in INMAS, DRDO, Delhi, India. He completed his M.Sc. and Ph.D. in Biomedical Science from Delhi University, India. He also has another M.Sc. degree in Bioinformatics from Punjab Technical University, India. In year 2009, he joined INMAS, DRDO, Delhi, India, as Scientist 'C'. He is presently working in the area of stem cell research, microencapsulation, regenerative medicine, tissue engineering and omics data mining and analysis for repairing/ regenerating various types of tissues for Defence application. He has been awarded with many fellowships, project grants, and has published many articles including manuscripts, patents, book chapters etc. Neeraj Kumar Satija Senior Scientist, System Toxicology and Health Risk Assessment, CSIR-Indian Institute of Toxicology Research, Lucknow, India. Dr. Neeraj Kumar Satija PhD is working as a Senior Scientist at CSIR-Indian Institute of Toxicology Research, Lucknow, India. He completed his B.Tech and M.Tech in Biotechnology from School of Biotechnology, Guru Gobind Singh Indraprastha University, Delhi, India. Thereafter, he undertook doctoral studies at Institute of Nuclear Medicine and Allied Sciences, Delhi, India, elucidating role of Wnt signaling and its downstream target genes in mediating osteoblast differentiation of human mesenchymal stem cells, and identified lithium as a priming agent for enhancing osteogenic differentiation potential of mesenchymal stem cells. In 2014, he joined CSIR-Indian Institute of Toxicology Research, Lucknow, India, as a Scientist. His group is working in varied disciples such as stem cell toxicology, embryonic stem cell differentiation, leukemia chemoresistance and wound healing. He has mentored a number of graduate/post-graduate students and is guiding Ph.D. scholars. Pawan Kumar Raghav Researcher, University of California, San Francisco.. Dr. Pawan Kumar Raghav is currently a researcher the School of Medicine, Department of Surgery, University of California, San Francisco. He is developing novel approaches for investigating immune/inflammatory mechanisms of allograft injury and discovering new biomarkers and therapeutics in solid organ and bone marrow transplantation. He is the recipient of several awards and honors, including the ICMR Travel Award to deliver an oral talk in 11th world congress & expo on cell & stem cell research in Orlando, FL; Research Excellence Award from the Institute of Scholars, best Research Award from Science Father, and was invitated to present the research proposal at BioMed X GmbH, Germany. He has published more than 40 publications, including international research articles, book chapters, books, and intellectual property rights for patents. He is also reviewer and editor of special collections for several international journals and books. Nishant Tyagi Senior Research Scholar, Stem Cell & Gene Therapy Research Group, Institute of Nuclear Medicine and Allied Sciences, Delhi, India. Nishant Tyagi MSc is an Indian-born Senior Research Fellow, presently working at Stem Cells and Gene Therapy Research Group, Institute of Nuclear Medicine and Allied Sciences under Defence Research & Development Organisation, India. He graduated from Kirorimal College, University of Delhi, India, and completed his master's degree from Jamia Hamdard, New Delhi, India, in Biotechnology. He is a recipient of several awards and fellowships like NET-JRF, IIT GATE, and DRDO fellowship. He joined the Stem Cells and Gene Therapy Research Group in 2018 and has maintained a proactive approach to the research project and input ideas along with solid knowledge and research experience in biomaterial science. He is currently working under the guidance of Dr. Yogesh Kumar Verma, Senior Scientist, INMAS, in multiple defense-funded projects and has published several publications and filed many patents. Subodh Kumar Senior Research Scholar, Stem Cell and Gene Therapy Research Group, Institute of Nuclear Medicine and Allied Sciences, Delhi, India. Subodh Kumar MSc is an Indian-born Senior Research Fellow, currently working in Stem Cells and Gene Therapy Research Group, Institute of Nuclear Medicine and Allied Sciences, DRDO, in the defence funded project. Over the past two and half years he has worked in many research projects in the AIIMS and INMAS. He has earned his B.Sc. degree from Hansraj College, Delhi University and M.Sc. degree (Medical Biotechnology) from Maharishi Dayanand University, Rohtak, Haryana, sponsored by Department of Biotechnology, Government of India (PG research fellow).He has also qualified, GATE and CSIR JRF fellowship conducted by IITs and CSIR on behalf of Government of India respectively. He joined PhD under the supervision of senior scientist Dr. Yogesh Kumar (Sc. E), INMAS, DRDO.
Subodh Kumar has published many research papers and book chapters.
He is correctly putting his intellect for the research community through his writing and brain-storming scientific ideas.
